In recent years, immunotherapy aimed at reactivating weakened immune cells in cancer patients has achieved remarkable results, especially immune checkpoint inhibitors, such as programmed cell death protein-1 (PD-1) and cytotoxic […]
Introduction Programmed death-ligand 1 (PD-L1) is a protein that is highly expressed on the surface of many cancer cells. As PD-L1’s receptor, PD-1 belongs to the immunoglobulin superfamily and can […]
Introduction Programmed cell death 1 (PD-1) is a costimulatory molecule that belongs to the CD28/CTLA-4 family. PD-1 recruits and activates an activation signaling pathway such as protein tyrosine phosphatase by binding […]
Announcement of the 2018 Nobel Prize in Physiology or Medicine by Professor Thomas Perlmann, Secretary of the Nobel Committee for Physiology or Medicine, on 1 October 2018. It was awarded […]
Announcement of the 2018 Nobel Prize in Physiology or Medicine by Professor Thomas Perlmann, Secretary of the Nobel Committee for Physiology or Medicine, on 1 October 2018. It was awarded jointly […]
With upgrading of technologies and better understanding of diseases, the death rate caused by cancers is considerably decreased. According to the 2017 Cancer Progress Report released by the American Association […]
Cancer is primarily a disease of the older adult with more than 50 % of new cases occurring in adults older than 65 years. The care of older adults with cancer can […]
Immunotherapy and immune checkpoint inhibition in particular present an exciting opportunity for the treatment of bladder cancer. Over the last 30 years, bladder cancer patients have seen few advances in the […]
The ability of the immune system to detect and eliminate cancer was first proposed over 100 years ago. Since then, T cells reactive against tumor-associated antigens have been detected in […]